TABLE 2.
Characteristics of liver injury and clinical outcomes in patients with SARS‐CoV‐2/HBV coinfection
| Reference | Total cases | HBV cases, n (%) | ALT (U/L) | AST (U/L) | TBIL (μmol/L) | ALP (U/L) | GGT (U/L) | Severe/critical ill, n (%) | Death, n (%) | Note |
|---|---|---|---|---|---|---|---|---|---|---|
| Lin et al 7 | 133 | 17 (12.8) | 33.0 | 31.2 | 15.10 | 75.00 | 36.00 | NA | 0 | Inactive HBV carriers with SARS‐CoV‐2 coinfection are at risk of greater liver injury |
| Yu et al 8 | 67 | 7 (10.4) | NA | NA | NA | NA | NA | 2 (28.6) | 0 | SARS‐CoV‐2 would not cause of HBV reactivation |
| Li et al 21 | 342 | 7 (2) | 31.0 | 31.0 | 12.7 | NA | NA | 0 | 0 | The abnormalities of liver function are not uncommon |
| Chen et al 22 | 326 | 20 (6.1) | 28.00 | 27.5 | 10.55 | 60 | 23.50 | 2 (10.0) | 0 | No evidence showed coexistence of HBV infection increases the liver injury in COVID‐19 patients |
| Wu et al 23 | 620 | 70 (11.3) | 50 | 40 | NA | NA | NA | 23 (32.8) | 0 | Higher rate of liver injury, coagulation disorders and severe/critical tendency and increased susceptibility |
| Zou et al 24 | 105 | 105 (100) | 23 | 28 | 8.3 | 62 | 24 | 56 (53.3) | 7 (6.67) | Liver injury in patients with SARS‐CoV‐2/HBV coinfection was associated with severity and poor prognosis of disease |
| Liu et al 25 | 347 | 21 (6.4) | 30.40 | 34.15 | 12.60 | NA | 28.50 | 1 (5.0) | 0 | Three patients had HBV reactivation. The median levels of liver biochemistries were no significant difference between two groups |
| Chen et al 29 | 123 | 15 (12.2) | 25.0 | 28.0 | 13.2 | 76.0 | 20.0 | 7 (46.7) | 2 (13.3) | The level of TBIL was higher in patients with SARS‐CoV‐2/HBV coinfection (P < .05) |
| Zhang et al 30 | 23 | 23 (100) | 38.6 | 31.6 | 24.9 | 73 | 32.3 | 5 (21.7) | 0 | 26% of HBV carriers with COVID‐19 had abnormal liver function test results at admission |
| Yip et al 31 | 5639 | 353 b | 28 | 32 | 8.62 a | NA | NA | NA | 8 (2.3) | Current and past HBV infections were not associated with more liver injury and mortality in COVID‐19 |
| 359 c | 23 | 30 | 8.62 a | NA | NA | NA | 21 (5.8) | |||
| Current study | 156 | 20 (12.8) | 35.0 | 47.5 | 7.52 a | 58.0 | 22.0 | 1 (5.0) | 0 | Elevated liver enzymes or laboratory abnormalities indicating hepatic exacerbation were not detected |
The data in the laboratory results are expressed as the median.
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma‐glutamyltransferase; HBV, hepatitis B virus; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2; TBIL, total bilirubin.
a
Data were converted from mg/dL to μmol/L.
b
Current HBV infection.
c
Past HBV infection.